Table 2.
Network meta-analysis for comparison of HbA1c changes from baseline, Body weight change from baseline, Percentage of patients achieving HbA1c <7 and Percentage of patients experiencing hypoglycemic events between the 2 groups
| Comparison | Drug1 | Drug2 | HbA1c change from baseline | Body weight change from baseline | Percentage of patients achieving HbA1c <7% | Percentage of patients experiencing hypoglycemic events | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Freq1 | Mean difference (SE) | p-value | Freq | Mean difference (SE) | p-value | Freq | Odds Ratio (SE) | p-value | Freq | Odds Ratio (SE) | p-value | |||
| Direct (1) | Linagliptin 5 mg | placebo | 8 | −0.644(.045) | 0 | 5 | 0.348(.283) | 0.217 | 6 | 0.712 (.153) | 0 | 6 | −0.625 (.244) | 0.01 |
| Direct (2) | Sitagliptin 100 mg | placebo | 13 | −0.284(.125) | 0.022 | 7 | −0.925 (.795) | 0.244 | 8 | 0.440(.261) | 0.091 | 14 | −0.820(.287) | 0.004 |
| Direct (3) | LIN 5 mg + MET | PLB+ MET | 4 | −.247(.283) | 0.383 | 2 | −2.489 (.191) | 0 | 3 | 0.924(.701) | 0.188 | 4 | −1.853 (.119) | 0 |
| Direct (4) | SIT 100 mg + MET | PLB+ MET | 7 | −.555(.157) | 0 | 4 | −0.201 (.839) | 0.811 | 5 | 0.667 (.446) | 0.135 | 5 | −0.427(.525) | 0.417 |
| Indirect (5) | Linagliptin 5 mg | Sitagliptin 100 mg | – | −0.359(.133) | <.05 | – | 1.273(.843) | >0.05 | – | 0.272 (.302) | >.05 | – | 0.195 (.377) | >.05 |
| Indirect (6) | LIN 5 mg + MET | SIT 100 mg + MET | – | 0.308(.324) | >.05 | – | −2.288(.860) | <0.05 | – | 0.257(.830) | >.05 | – | −1.426(.538) | <.05 |
1- Freq: frequency